In desmoplastic tumor samples, the expression of CD274 is significantly increased compared to non-desmoplastic tumor samples, suggesting that CRCLM patients with desmoplastic growth patterns should benefit from therapy with an immune checkpoint inhibitor for PD-L1. Here, CD274 is linked to neoplasm.